Kalaris Therapeutics Inc (KLRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 142,250 | 0 | 0 | N/A | 0 |
| Marketable Securities | 236,238 | 0 | 0 | N/A | 0 |
| Receivables | 169 | 0 | 0 | N/A | 0 |
| Other current assets | 423 | 0 | 0 | 0 | 0 |
| TOTAL | $383,941 | $0 | $0 | $N/A | $0 |
| Non-Current Assets | |||||
| PPE Net | 295 | N/A | N/A | N/A | N/A |
| Other Non-Current Assets | 9,474 | 0 | 0 | 0 | 0 |
| TOTAL | $9,769 | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $393,710 | $0 | $0 | $N/A | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,843 | 0 | 0 | 0 | 0 |
| Accrued Expenses | 7,849 | 0 | 0 | N/A | 0 |
| Other current liabilities | 641 | 0 | 0 | N/A | 0 |
| TOTAL | $13,521 | $0 | $0 | $N/A | $0 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 6,286 | 0 | 0 | 0 | 0 |
| TOTAL | $6,286 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $19,807 | $0 | $0 | $N/A | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 2,832 | 938 | N/A | N/A | N/A |
| Common Shares | 7 | 0 | 0 | N/A | 0 |
| Retained earnings | -99,904 | 0 | 0 | N/A | 0 |
| Other shareholders' equity | -41 | 0 | 0 | 0 | 0 |
| TOTAL | $373,903 | $0 | $0 | $N/A | $0 |
| Total Liabilities And Equity | $393,710 | $0 | $0 | $0 | $0 |